Helicobacter Pylori and Steps for its Elimination: A Review

Manash Pratim Sarma; Manash Pratim Sarma

Authors

Manash Pratim Sarma
Manash Pratim Sarma

Keywords:

helicobacter pylori, antimicrobial resistance, eradication, therapy

Abstract

The only host for H. pylori is human and it is found to be present in stomach, duodenum, oesophagus and rectum. H. pylorus is responsible for causing chronic infections and therefore its complete eradication from the society is very much essential. This article therefore aims to review the recent treatment options prevalent for the eradication of this dreadful disease.

Downloads

How to Cite

Helicobacter Pylori and Steps for its Elimination: A Review. (2016). Global Journal of Medical Research, 16(F4), 31-36. https://medicalresearchjournal.org/index.php/GJMR/article/view/1147

Download Citation

References

Yao-Jong Yang, Bor-Shyang Sheu (2016) Metabolic Interaction of Helicobacter pylori Infection and Gut Microbiota. 4(1), 15.

Nicholas Martinez, Md Karthik Garapati, M, Charles Randall, M (2014) Management of Helicobacter Pylori Infection. 2, 1.

W Yuan, Li Yumin, Yang Kehu, Ma Bin, Guan Quanlin (2010) Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials. 45, 665-676.

B Egan, M Katicic, H O'connor, C O'morain (2007) Treatment of Helicobacter pylori. 12, 31-37.

M Janssen, L Hendrikse, S De Boer, R Bosboom, W De Boer, R Laheij, J Jansen (2006) Helicobacter pylori antibiotic resistance in a Dutch region: trends over time. 64, 191-195.

Helicobacter pylori Eradication: Decision Making in Clinical Practice, MP Sharma. 64, 378-381.

(2010) World Gastroenterology Organisation Global Guideline. 45(5), 383-388.

A Olokoba, O Obateru1, M Bojuwoye (2013) Helicobacter pylori eradication therapy: A review of current trends. 54, 1-4.

A Zullo, D Vaira, N Vakil, C Hassan, L Gatta, C Ricci (2003) High eradication rates of Helicobacter pylori with a new sequential treatment. 17, 719-726.

Brian Egan, Colm O'morain (2007) A historical perspective of Helicobacter gastroduodenitis and its complications. 21(2), 335-346.

P Malfertheiner, F Megraud, C O'morain, F Bazzoli, E El-Omar, D Graham, R Hunt, T Rokkas, N Vakil, E Kuipers (2007) Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. 56(6), 772-781.

J Chung, G Lee, J Han (2011) The trends of one-week first-line and second-line eradication therapy for Helicobacter pylori infection in Korea. 58, 246-250.

Jai Yoon, G Baik, K Sohn (2012) Trends in the eradication rates ofHelicobacter pyloriinfection for eleven years. 18(45), 6628.

Y Jung, S Lee, C Park (2014) Trends in the eradication rates of Helicobacter pylori infection in Daegu and Gyeongsangbuk-do, Korea: multicenter study over 13 years. 63, 82-89.

H Jeon, G Kim (2014) Does standard triple therapy still have a role in first-line Helicobacter pylori eradication in Korea?. 29, 16.

Eun Gong, Sung-Cheol Yun, Hwoon-Yong Jung, Hyun Lim, Kwi-Sook Choi, Ji Ahn, Jeong Lee, Do Kim, Kee Choi, Ho Song, Gin Lee, Jin-Ho Kim (2014) Meta-Analysis of First-Line Triple Therapy forHelicobacter pyloriEradication in Korea: Is It Time to Change?. 29(5), 704.

D Graham, Y Lee, M Wu (2014) Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. 12, 3-186.

J Wu, J Liou, D Graham (2014) Evidencebased recommendations for successful Helicobacter pylori treatment. 8, 21-28.

Takahisa Furuta, David Graham (2010) Pharmacologic Aspects of Eradication Therapy for Helicobacter pylori Infection. 39(3), 465-480.

E Gené, X Calvet, R Azagra, J Gisbert (2003) Triple vs quadruple therapy for treating Helicobacter pylori infection: an updated meta-analysis. 18, 543-544.

D Graham, A Shiotani (2012) Which Therapy for Helicobacter pylori Infection. 143, 10-12.

L Fischbach, E Evans (2007) Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. 26, 343-357.

Bojan Tepes, Anthony O'connor, Javier Gisbert, Colm O'morain (2012) Treatment of Helicobacter pylori infection 2012. 17(s1), 36-42.

M Osato, R Reddy, S Reddy, R Penl, H Malaty (2001) Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. 161, 1217-1220.

L Laine, R Hunt, H El-Zimaity, B Nguyen, M Osato (2003) Bismuth based quadruple therapy using a single capsule of bismuth biskal citrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenalulcer patients: A prospective, randomized, multicenter North American trial. 98, 562-567.

L Laine (2003) Is it time for quadruple therapy to be first line?. 17, 33B-35B.

R Cianci, M Montalto, F Pandolfi, G Gasbarrini, G Cammarota (2006) Third-line rescue therapy for Helicobacter pylori infection. 12, 2313-2319.

J Hua, P Zheng, T Fong, M Khin, H Bow (1998) Helicobacterpylori acquistion of metronidazole resistance by natural transformation in vitro. 4, 385-387.

G Cammarota, A Martino, G Pirozzi, R Cianci, G Branca, E Nista, A Cazzato, O Cannizzaro, L Miele, A Grieco, A Gasbarrini, G Gasbarrini (2004) High efficacy of 1‐week doxycycline‐ and amoxicillin‐based quadruple regimen in a culture‐guided, third‐line treatment approach for Helicobacter pylori infection. 19(7), 789-795.

K Choi, W Chung, K Lee, C Paik, E Kim, B Kang (2011) Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: A double-blind, randomized controlled trial. 26, 785-790.

Helicobacter pylori -Current Therapy and Future Therapeutic Strategies, Rajinikanth Siddalingam and Kumarappan Chidambaram. 10, 279-302.